The paradigm of cancer diagnostics has fundamentally shifted in 2026, with the Liquid Biopsy Market reaching a pivotal valuation of $14.23 billion. This year, the industry is moving away from being a "secondary confirmation" tool to becoming a primary screening method. In 2026, the rise of "Multi-Cancer Early Detection" (MCED) tests allows a single blood draw to screen for over 50 types of...